<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-76416" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Granulomatosis With Polyangiitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rout</surname>
            <given-names>Preeti</given-names>
          </name>
          <aff>Wilson Case Western University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Qurie</surname>
            <given-names>Ahmad</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Rout declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ahmad Qurie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-76416.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Granulomatosis with polyangiitis is a rare form of vasculitis affecting small vessels. Hallmark features include necrotizing granulomas and pauci-immune vasculitis, most commonly affecting the upper respiratory tract, lungs, and kidneys. Antineutrophil cytoplasmic antibody&#x02013;associated vasculitis diseases comprise granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. These&#x000a0;syndromes share overlapping etiologies and clinical presentations, particularly granulomatosis with polyangiitis and microscopic polyangiitis. Due to the variable systemic manifestations, a high index of suspicion is required for accurate diagnosis. Despite their rarity, these diseases are associated with significant morbidity and mortality and have been the focus of numerous recent clinical trials. These trials have generated extensive data and treatment recommendations. This activity describes the clinical presentation, evaluation, and treatment of granulomatosis with polyangiitis, highlighting the role of the interprofessional team in treating patients with this disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between granulomatosis with polyangiitis and other forms of vasculitides, including systemic lupus erythematosus, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis.</p></list-item><list-item><p>Screen patients with upper respiratory tract, lung, and kidney symptoms for potential signs of granulomatosis with polyangiitis to ensure early detection and intervention.</p></list-item><list-item><p>Implement evidence-based treatment protocols for managing granulomatosis with polyangiitis, including the use of immunosuppressive therapies.</p></list-item><list-item><p>Collaborate with an interprofessional healthcare team, including rheumatologists, nephrologists, and pulmonologists, to provide comprehensive care for patients with granulomatosis with polyangiitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=76416&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=76416">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-76416.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Granulomatosis with polyangiitis (GPA), formerly known as Wegener's granulomatosis, is a necrotizing vasculitis affecting small to medium-sized vessels. GPA is part of a spectrum of disorders known as antineutrophil cytoplasmic antibody (ANCA)&#x02013;associated vasculitides. The 3 main ANCA-associated vasculitides are GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss syndrome). This classification was established at the 2012 Chapel Hill Consensus Conference on the Nomenclature of Systemic Vasculitides.<xref ref-type="bibr" rid="article-76416.r1">[1]</xref>&#x000a0;GPA is characterized by a pulmonary-renal syndrome associated with otorhinolaryngological manifestations.&#x000a0;</p>
        <p>The first case of GPA was described by German medical student Heinz Klinger in 1931. In 1936, a German pathologist, Friedrich Wegener, described 3 cases of peculiar small-medium vessel vasculitis with granulomatous inflammation and identified the disorder as a distinct form of vasculitis. In 1954, Godman and Churg published a review involving 22 cases, and the disease was universally known as Wegener's granulomatosis.<xref ref-type="bibr" rid="article-76416.r2">[2]</xref> In 1989, Wegener was awarded a Master Clinician Prize by the American College of Chest Physicians. In 2000, Wegener's Nazi ties came to light, and a movement began to rename the disease in the clinical community. The board of directors of the American College of Rheumatology (ACR), the American Society of Nephrology, and the European League Against Rheumatism recommended a switch to disease-descriptive nomenclature. Hence, the disease was renamed GPA.<xref ref-type="bibr" rid="article-76416.r3">[3]</xref></p>
        <p>Please see StatPearls' companion resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/32717">ANCA Positive Vasculitis</ext-link>," "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/25111">Microscopic Polyangiitis</ext-link>," and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/19543">Eosinophilic Granulomatosis with Polyangiitis</ext-link>,"&#x000a0;for more information.</p>
      </sec>
      <sec id="article-76416.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Several complex interactions involving genetics and microbes have been implicated in the etiology of GPA. The presumption that ANCAs are responsible for inflammation in GPA is now widely accepted. Defective immune-regulatory responses to environmental factors, such as infection or autoantigens, can lead to excessive production of cytokines, which in turn may develop inflammatory granulomatous vascular lesions.<xref ref-type="bibr" rid="article-76416.r4">[4]</xref>&#x000a0;</p>
        <p>Understanding the 2 primary types of&#x000a0;ANCAs&#x02014;anti-proteinase 3 (PR3) and anti-myeloperoxidase (MPO)&#x02014;is crucial for comprehending the disease process. Some studies suggest that the specific type of ANCA may have better prognostic value compared to the clinical presentation of the disease. ANCA in GPA typically reacts with PR3, a serine proteinase prevalent in neutrophil granulocytes. When ANCA binds to PR3, it activates neutrophils, increasing their adherence to the endothelium and triggering degranulation, which can damage endothelial cells.<xref ref-type="bibr" rid="article-76416.r5">[5]</xref>&#x000a0;In GPA cases, anti-PR3 is positive in about 75% of cases; anti-MPO antibody is positive in about 10% of cases; fewer than 10% are ANCA-negative.<xref ref-type="bibr" rid="article-76416.r5">[5]</xref>&#x000a0;With MPA, anti-MPO is positive in about 70% of cases.<xref ref-type="bibr" rid="article-76416.r3">[3]</xref></p>
        <p>Neutrophils from GPA patients are more likely to produce neutrophil extracellular traps and exhibit lower DNAse I activity, leading to decreased clearance of neutrophil extracellular traps.&#x000a0;Neutrophil extracellular traps are composed of decondensed chromatin and intracellular granules that capture cell components.<xref ref-type="bibr" rid="article-76416.r6">[6]</xref><xref ref-type="bibr" rid="article-76416.r7">[7]</xref> Anti-PR3 binds to neutrophils, leading to degranulation, reactive oxygen species, adhesion to endothelial cells, and secretion of pro-inflammatory cytokines, especially interleukin-8.<xref ref-type="bibr" rid="article-76416.r5">[5]</xref>&#x000a0;Although neutrophils are an integral part of innate immunity, adaptive immunity responses are also significant. B-cells specific to PR-3 are associated with disease activity and risk of relapse.<xref ref-type="bibr" rid="article-76416.r8">[8]</xref></p>
        <p>Genetic associations in GPA include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>A defective allele for alpha-1 antitrypsin</p>
          </list-item>
          <list-item>
            <p>Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is involved in T-cell activation</p>
          </list-item>
          <list-item>
            <p>PR3 gene</p>
          </list-item>
          <list-item>
            <p>Major histocompatibility complex, class II, DP alpha-1 (HLA-DP) gene</p>
          </list-item>
          <list-item>
            <p>Certain types of FC gamma receptor III b on the surface of neutrophils and macrocytes&#x000a0;or monocytes&#x000a0;<xref ref-type="bibr" rid="article-76416.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>Infections: In addition to the initiation and exacerbation of the vasculitic process, infectious agents have also been known to modulate the clinical phenotype of the disease.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Bacterial: Colonization with <italic toggle="yes">Staphylococcus aureus</italic> has been hypothesized as an initiating factor for inflammation observed in GPA because it is associated with neutrophil extracellular trap release.<xref ref-type="bibr" rid="article-76416.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Viral: Association with various viruses, including hepatitis C virus, cytomegalovirus, Epstein-Barr virus, and parvovirus, have been reported.<xref ref-type="bibr" rid="article-76416.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drugs Linked to Antineutrophil Cytoplasmic Antibody&#x02013;Associated Vasculitis</bold>
</p>
        <p>Certain medications can induce ANCA-associated vasculitis, typically manifesting as rapidly progressive glomerulonephritis. Specifically, a high MPO titer is common. Levamisole, which is often found in contaminated cocaine,&#x000a0;can cause the elevation of both anti-MPO&#x000a0;and anti-PR3 antibodies, along with other autoantibodies, skin lesions, and arthralgias. Treatment is the same as that of other ANCA-associated rapidly progressive glomerulonephritis cases, but possibly with shorter induction, and prolonged maintenance is typically unnecessary. Once the drug is discontinued, relapse is uncommon, unlike disease associated with PR3/MPO. The most common offending medications include these:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hydralazine</p>
          </list-item>
          <list-item>
            <p>Propylthiouracil and methimazole</p>
          </list-item>
          <list-item>
            <p>Allopurinol</p>
          </list-item>
          <list-item>
            <p>Sulfasalazine</p>
          </list-item>
          <list-item>
            <p>Minocycline</p>
          </list-item>
          <list-item>
            <p>Penicillamine</p>
          </list-item>
          <list-item>
            <p>Rifampicin</p>
          </list-item>
          <list-item>
            <p>Aminoguanidine</p>
          </list-item>
          <list-item>
            <p>Sofosbuvir</p>
          </list-item>
          <list-item>
            <p>Anti-tumor necrosis factor-alpha therapy for rheumatoid arthritis and ankylosing spondylitis&#x000a0;<xref ref-type="bibr" rid="article-76416.r11">[11]</xref></p>
          </list-item>
        </list>
        <p><bold>Double-Positive Antibody Disease</bold>&#x000a0;</p>
        <p>Also called dual antibody disease, this type of crescentic glomerulonephritis is associated with a positive ANCA and anti-glomerular basement membrane (GBM) antibody. Some studies indicate that 10% to 50% of patients with anti-GBM disease have detectable ANCA, typically anti-MPO. In contrast, up&#x000a0;to 10% of patients with ANCA-associated vasculitis also have circulating anti-GBM antibodies.<xref ref-type="bibr" rid="article-76416.r12">[12]</xref>&#x000a0;Generally, the positive ANCA precedes the anti-GBM antibodies;&#x000a0;therefore, it is postulated that ANCA leads to the anti-GBM antibodies by exposing epitopes on the GBM. Renal manifestations follow an anti-GBM pattern, whereas systemic symptoms are similar to those of ANCA vasculitis.<xref ref-type="bibr" rid="article-76416.r13">[13]</xref><xref ref-type="bibr" rid="article-76416.r14">[14]</xref>&#x000a0;This double-positive characteristic comes into play&#x000a0;during treatment selection.<xref ref-type="bibr" rid="article-76416.r8">[8]</xref><xref ref-type="bibr" rid="article-76416.r15">[15]</xref></p>
      </sec>
      <sec id="article-76416.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Among the 3 ANCA-associated vasculitides, GPA is the most common. The annual worldwide incidence of GPA is estimated to be 10 to 20 cases per million based on the geographical location. A higher incidence is noted in the colder regions. The prevalence of GPA in European and American populations is about 120 to 140 per million.<xref ref-type="bibr" rid="article-76416.r16">[16]</xref>&#x000a0;A national study in the Netherlands on ANCA-associated vasculitis found that 167 patients (73%) were diagnosed with GPA, 54 (24%) with MPA, and 9 (4%) with EGPA. This distribution is similar to other European registries.<xref ref-type="bibr" rid="article-76416.r17">[17]</xref>&#x000a0;</p>
        <p>GPA is more commonly reported in Whites, although it can be observed in all racial and ethnic groups.&#x000a0;The onset of GPA occurs between 45 and 60 years, but a small proportion (3%-7%) affects children and adolescents. Children younger than 18 have a female-to-male predominance of about 2:1, while in adults, the ratio is 1:1.<xref ref-type="bibr" rid="article-76416.r18">[18]</xref></p>
      </sec>
      <sec id="article-76416.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The etiology of GPA is attributed to ANCA, which causes an immune-mediated vasculitis of small- and medium-sized vessels, primarily affecting the ears, nose, throat, lungs, and kidneys. The primary morbidity of the GPA is related to necrotizing sinusitis, pulmonary capillaritis, and glomerulonephritis.<xref ref-type="bibr" rid="article-76416.r5">[5]</xref></p>
        <p>The formation of granulomas in GPA begins with the development of neutrophilic microabscesses. The granulomas in GPA ultimately result in partial or total occlusion of blood vessels. The granulomas in GPA are not well-formed, unlike the ones in sarcoidosis or tuberculosis, and consist of giant cells surrounded by plasma cells, lymphocytes, and dendritic cells. These cells can damage the submucosa and penetrate the surrounding tissues, cartilage, or bone, resulting in necrosis and permanent deformities.<xref ref-type="bibr" rid="article-76416.r4">[4]</xref><xref ref-type="bibr" rid="article-76416.r19">[19]</xref></p>
        <p>A significant overlap exists between the 3 ANCA-associated vasculitides, particularly GPA and MPA. MPA is a necrotizing vasculitis primarily involving small vessels and is less likely to involve the upper airways; pathology does not demonstrate granulomas. MPA is associated with pulmonary fibrosis, a condition that is rare in GPA.<xref ref-type="bibr" rid="article-76416.r20">[20]</xref></p>
      </sec>
      <sec id="article-76416.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathological evaluation of various organs, including kidneys, skin, and lungs, can be performed to detect vasculitis and immune deposits. The lung is the most common site for biopsy, followed by renal biopsy.</p>
        <p>Lung:</p>
        <list list-type="bullet">
          <list-item>
            <p>A lung biopsy shows granulomas surrounded by palisading histiocytes and giant cells with central necrosis. The central necrosis leads to liquefaction&#x000a0;or coagulative necrosis in the lungs with profuse eosinophils and multinucleated giant cells. Necrotizing or granulomatous vasculitis is found in small arteries and veins, and the lumens can be occluded by granulomas or thrombi.<xref ref-type="bibr" rid="article-76416.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Given the patchy involvement of GPA, targeted lung biopsy is recommended rather than biopsy without correlation to imaging. CT scans and 18-F-fluorodeoxyglucose positron emission/CT scans can also be used to identify active lesions to increase the biopsy yield. Avoiding necrotic areas is also preferable.<xref ref-type="bibr" rid="article-76416.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>Kidney:</p>
        <list list-type="bullet">
          <list-item>
            <p>Light microscopy shows necrotizing and crescentic glomerulonephritis. Cellular, microcellular, and fibrous crescents may all be present, representing different stages of disease progression.&#x000a0;Immunofluorescence staining is typically negative or very light for immunoglobulins (Ig) or complement. If present, the small amounts are more likely to be present in a segmental distribution (unlike the diffuse distribution of immune complex glomerulonephritis).<xref ref-type="bibr" rid="article-76416.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>The percentage of capsular rupture, fibrous crescents, tubular atrophy, and interstitial fibrosis are linked with increased progression to end-stage renal disease.<xref ref-type="bibr" rid="article-76416.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22288">Rapidly Progressive Glomerulonephritis</ext-link>," for more information.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-76416.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>GPA typically presents with a triad of symptoms as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Upper respiratory tract,&#x000a0;including sinusitis, crusting rhinitis, saddle nose deformity, otitis media, mastoiditis, and hearing loss, and lower respiratory tract, such as lung nodules and alveolar hemorrhage</p>
          </list-item>
          <list-item>
            <p>Systemic vasculitis</p>
          </list-item>
          <list-item>
            <p>Kidney involvement, such as glomerulonephritis&#x000a0;<xref ref-type="bibr" rid="article-76416.r23">[23]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>GPA shows a significant overlap with MPA. Alveolar hemorrhage and crescentic necrotizing glomerulonephritis are also observed in MPA.&#x000a0;</p>
        <p>
<bold>Generalized Systemic Symptoms</bold>
</p>
        <p>GPA typically presents with nonspecific symptoms of generalized systemic disease, including fever, malaise, weight loss, polyarthralgia, and myalgia.<xref ref-type="bibr" rid="article-76416.r24">[24]</xref></p>
        <p>Systemic manifestations are as follows:&#x000a0;<xref ref-type="bibr" rid="article-76416.r24">[24]</xref></p>
        <p><bold>Upper respiratory tract involvement:</bold> Studies show that approximately 90% of patients experience upper respiratory tract issues. Early symptoms often include nasal and sinus pain, sinus stuffiness, purulent nasal discharge, nasal ulcerations, epistaxis, and otitis media. Clinical signs such as sinusitis, crusting rhinitis, otitis media, mastoiditis, and hearing loss should alert for GPA. Nasal inflammation can lead to septal perforation or nasal bridge collapse, causing a saddle nose deformity.<xref ref-type="bibr" rid="article-76416.r24">[24]</xref>&#x000a0;</p>
        <p><bold>Lower respiratory tract involvement:&#x000a0;</bold>Symptoms include cough, hemoptysis, dyspnea, sometimes pleuritic chest pain, and tracheal obstruction can be noted. Nearly 50% of patients initially present with bilateral or unilateral pulmonary infiltrates. Pulmonary nodules (referred to as coin lesions) are common. Pleural effusion has also been reported in 15% to 20% of cases. Diffuse pulmonary hemorrhage is a significant cause of morbidity and mortality in these patients.<xref ref-type="bibr" rid="article-76416.r25">[25]</xref><xref ref-type="bibr" rid="article-76416.r26">[26]</xref></p>
        <p><bold>Renal involvement:&#x000a0;</bold>Upon presentation, renal involvement is noted in only 10%&#x000a0;to 20% of cases, but glomerulonephritis eventually develops in 80% of patients within 2 years of disease onset. The most common manifestation is rapidly progressive crescentic glomerulonephritis, leading to chronic kidney disease or end-stage renal disease.</p>
        <p><bold>Eye involvement:&#x000a0;</bold>Eye&#x000a0;involvement occurs in more than half of the people with the disease. Scleritis and conjunctivitis are the most common manifestations.&#x000a0;Scleritis can lead to necrotizing anterior scleritis, eventually causing blindness. Peripheral ulcerative keratitis is the most significant corneal complication of GPA that could lead to corneal melt syndrome. Other manifestations include episcleritis and anterior uveitis. In 10% to 15% of the patients, orbital masses in the retrobulbar region can occur, known as pseudotumors. These pseudotumors can cause diplopia, proptosis, or vision loss. Nasolacrimal duct obstruction is frequently observed in GPA.<xref ref-type="bibr" rid="article-76416.r27">[27]</xref></p>
        <p><bold>Ear involvement:</bold> Both conductive and sensorineural hearing loss are typical of the disease. Conductive hearing loss often results from auditory tube dysfunction secondary to nasopharyngeal disease. Some individuals may also experience sensorineural hearing loss and vestibular dysfunction. Middle ear involvement, including serous otitis media and mastoiditis, is also observed.&#x000a0;</p>
        <p><bold>Skin:&#x000a0;</bold>Dermatologic involvement is reported in 50% to 60% of patients with GPA, with purpura commonly involving the lower extremities. Other common manifestations, including cutaneous nodules, particularly involving the olecranon regions, are common and can be mistaken for rheumatoid arthritis. Less commonly, ulcers, papules, vesicles, and subcutaneous nodules (granulomas) may occur.&#x000a0;</p>
        <p><bold>Nervous system:&#x000a0;</bold>Nervous system involvement is observed in about 30% to 40% of the patients, with peripheral neuropathies being the most common. Neuropathy could lead to mononeuritis multiplex. Cranial neuropathies, pachymeningitis, seizures, and cerebritis have also been reported.&#x000a0;</p>
        <p><bold>Musculoskeletal:</bold> Arthralgia and myalgia are observed in 70% of patients. Joint symptoms are common, but diagnosis with this alone is rarely made without other manifestations. Arthralgias are more common&#x000a0;compared to arthritis. The presence of joint pains, along with subcutaneous nodules and rheumatoid factor positivity, can often lead to misdiagnosis.&#x000a0;</p>
        <p><bold>Cardiac:</bold> Cardiac involvement is not common and involves valvular lesions or insufficiency, pericarditis, and coronary arteritis.</p>
        <p>
<bold>Childhood GPA</bold>
</p>
        <p>GPA is significantly more common in adults, particularly at older ages, compared to children.&#x000a0;Although the clinical presentation in children is generally similar to that in adults, one notable difference is the increased risk of subglottic stenosis. Patients younger than 20 are 5 times more likely than adults to develop subglottic stenosis, a dangerous complication. Symptoms of tracheobronchial involvement include hoarseness, cough, dyspnea, stridor, and wheezing. According to the ARChiVe (A Registry for Children with Vasculitis), which includes 65 children with GPA, 74% had pulmonary involvement, with 52% experiencing a chronic cough.<xref ref-type="bibr" rid="article-76416.r20">[20]</xref></p>
        <p>The most common manifestations are upper airway involvement (82%), nephropathy&#x000a0;(65%), and lower respiratory tract disease (61%). Systemic symptoms are prevalent, occurring in about 73% of cases. Sinonasal disease is often initially misdiagnosed as allergic rhinitis or rhinosinusitis. The longstanding disease can lead to the destruction of the nasal cartilage, resulting in saddle-nose deformity. Other upper airway manifestations include otitis, mastoiditis, oral ulcers, mucocele, and hearing loss.<xref ref-type="bibr" rid="article-76416.r20">[20]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-76416.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluating a patient with suspected GPA involves a complete clinical, laboratory, radiological, and histopathological assessment. A thorough clinical evaluation is crucial to determine the sites and extent of disease involvement.</p>
        <p>The 2022 ACR/European Alliance of Associations for Rheumatology (EULAR) classification criteria for GPA includes the following weighted criteria:&#x000a0;<xref ref-type="bibr" rid="article-76416.r28">[28]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Bloody nasal discharge, nasal crusting, or sinonasal congestion (+3)</p>
          </list-item>
          <list-item>
            <p>Cartilaginous involvement (+2)</p>
          </list-item>
          <list-item>
            <p>Conductive or sensorineural hearing loss (+1)</p>
          </list-item>
          <list-item>
            <p>Cytoplasmic ANCA or anti-PR3 ANCA positivity (+5)</p>
          </list-item>
          <list-item>
            <p>Pulmonary nodules, mass, or cavitation on chest imaging (+2)</p>
          </list-item>
          <list-item>
            <p>Granuloma or giant cells on biopsy (+2)</p>
          </list-item>
          <list-item>
            <p>Inflammation or consolidation of the nasal/paranasal sinuses on imaging (+1)</p>
          </list-item>
          <list-item>
            <p>Pauci-immune glomerulonephritis (+1)</p>
          </list-item>
          <list-item>
            <p>Perinuclear ANCA or anti-MPO ANCA positivity (&#x02212;1)</p>
          </list-item>
          <list-item>
            <p>Eosinophil count more than 1&#x000d7;10<sup>9</sup>&#x000a0;cells/L (&#x02212;4)</p>
          </list-item>
        </list>
        <p>After excluding mimics of vasculitis, a patient diagnosed with small- or medium-vessel vasculitis could be classified as having GPA if the cumulative score is 5 or more points. When these criteria were tested in the validation dataset, the sensitivity was 93%, and the specificity was 94%.<xref ref-type="bibr" rid="article-76416.r28">[28]</xref></p>
        <p>
<bold>Other Diagnostic Criteria</bold>
</p>
        <p>Various diagnostic criteria have been proposed to diagnose GPA and distinguish the disease from other forms of vasculitis.</p>
        <p>The ACR criteria include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Urinary sediment showing red blood cell casts or more than 5 red blood cells per high-power field,</p>
          </list-item>
          <list-item>
            <p>Abnormal findings on chest radiography</p>
          </list-item>
          <list-item>
            <p>Oral ulcer or nasal discharge</p>
          </list-item>
          <list-item>
            <p>Granulomatous inflammation on biopsy.</p>
          </list-item>
        </list>
        <p>The presence of 2 or more of the 4 criteria mentioned above is associated with a 92% specificity and 88% sensitivity.<xref ref-type="bibr" rid="article-76416.r25">[25]</xref></p>
        <p>The ELK (E for ears, nose, and throat or upper respiratory tract; L for lung; and K for kidney) proposed by DeRemee uses ANCA to diagnose. According to these criteria, any typical manifestation involving the ELK, along with positive c-ANCA or typical histopathological finding, qualifies for a diagnosis of GPA.<xref ref-type="bibr" rid="article-76416.r26">[26]</xref></p>
        <p>
<bold>Antineutrophil Cytoplasmic Antibody Testing</bold>
</p>
        <p>Although ANCA serology is essential for diagnosing ANCA-associated vasculitis, the diagnosis cannot rely solely on ANCA testing, as positive results may also be found in other inflammatory conditions. Often, these ANCAs are not specific to PR3 or MPO; therefore, they cannot be visualized by the more specific immunoassay techniques. Instead, they may be visualized by the less specific immunofixation method.<xref ref-type="bibr" rid="article-76416.r29">[29]</xref>&#x000a0;Some less-specific ANCA antigens include cathepsin G, lactoferrin, elastase, defensin, &#x003b1;-enolase, moesin, leukocidin, and bactericidal permeability&#x02013;increasing protein.&#x000a0;The pathogenicity of these antigens is believed to be low.<xref ref-type="bibr" rid="article-76416.r3">[3]</xref></p>
        <p>ANCA serology for MPO or PR3 is positive in about 90% of GPA and MPO cases, whereas it is positive in about 40% of EGPA cases.<xref ref-type="bibr" rid="article-76416.r30">[30]</xref>&#x000a0;A study found that GPA is 80% positive for anti-PR3, 15% positive for anti-MPO, and 5% ANCA-negative.<xref ref-type="bibr" rid="article-76416.r3">[3]</xref> Anti-PR3 antibodies are about 90% sensitive for diagnosing GPA.<xref ref-type="bibr" rid="article-76416.r5">[5]</xref><xref ref-type="bibr" rid="article-76416.r31">[31]</xref>&#x000a0;Although considered sensitive and specific for GPA, ANCA positivity has also been noted in 15% to 20% of patients with systemic lupus erythematosus, especially those with lupus nephritis.<xref ref-type="bibr" rid="article-76416.r7">[7]</xref></p>
        <p>Lysosome-associated membrane protein-2 (LAMP-2) is a protein that is believed to provide structural integrity to lysosomes and help prevent autodigestion. LAMP-2 antibodies are particularly interesting in ANCA-associated vasculitis because they are found in patients with MPO and PR3 antibodies and may contribute to the disease pathology. In addition, LAMP-2 antibodies have been found in patients with active ANCA-associated vasculitis who are negative for antibodies to MPO and PR3. Some evidence also suggests that LAMP-2 antibodies correlate better with active disease compared to MPO/PR3 antibodies.<xref ref-type="bibr" rid="article-76416.r32">[32]</xref></p>
        <p>ANCA can also be negative in some cases, particularly localized disease presentations. A study involving patients with localized GPA found that only 46% of patients were ANCA-positive and that ANCA positivity did not correlate with the risk of relapse, transition to systemic disease, or refractoriness to treatment.<xref ref-type="bibr" rid="article-76416.r33">[33]</xref> Another study found that PR3 levels correlated with disease activity in only about 25% of cases, suggesting that PR3 levels alone should not be used to measure clinical activity or response to treatment; interactions with other proteins may also be relevant.<xref ref-type="bibr" rid="article-76416.r5">[5]</xref></p>
        <p>Antigen-specific immunoassays are considered more sensitive compared to indirect immunofluorescence and are the more commonly used method in most places. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/20240">Antinuclear Cytoplasmic Antibody</ext-link>," for more information.</p>
        <p>
<bold>Radiology</bold>
</p>
        <p>Radiological evaluation of the sinuses, lungs, trachea, and orbits can be performed to assess the sites and extent of involvement. A chest x-ray and computed tomography (CT) scan of the lungs can be performed to identify pulmonary lesions and hemorrhage, which can help differentiate GPA from MPA.&#x000a0;</p>
        <p>A chest x-ray is abnormal in about 89% of cases. Nodular lesions are the most common radiologic finding. In children, these nodules typically range in size from 1 to 4 cm, while in adults, they can range from 1 to 10 cm. Without treatment, the nodules enlarge and can cavitate.<xref ref-type="bibr" rid="article-76416.r20">[20]</xref></p>
        <p>Given the patchy involvement of GPA, a targeted lung biopsy is recommended. CT scans and 18-F-fluorodeoxyglucose positron emission/CT scans can also be used to identify active lesions,&#x000a0;increasing the biopsy yield. When performing biopsies, it is preferable to avoid necrotic areas to ensure accurate diagnosis.<xref ref-type="bibr" rid="article-76416.r20">[20]</xref></p>
      </sec>
      <sec id="article-76416.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The ACR and EULAR are developing criteria for treating ANCA-associated vasculitis. Based on new clinical trial data, recent recommendations propose classifying the disease as either organ/life-threatening&#x000a0;or not, rather than severe or not severe categories. Examples of organ/life-threatening disease manifestations include glomerulonephritis, pulmonary hemorrhage, cardiac involvement, or retro-orbital disease. Examples of non-organ/life-threatening processes include skin involvement, myositis, and non-cavitating pulmonary nodules.<xref ref-type="bibr" rid="article-76416.r31">[31]</xref>&#x000a0;</p>
        <p>The treatment of GPA involves the use of immunosuppressive agents in a variety of combinations. Treatment is classified into 2 phases&#x02014;the induction phase and the maintenance phase. Commonly used agents are cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and plasmapheresis if indicated.&#x000a0;</p>
        <p>The recommendations listed here apply to both GPA and MPA. EGPA involves a different recommendation set. One key difference between GPA and MPA is patients diagnosed with the clinical syndrome of GPA and PR3-ANCA positivity have an increased relapse risk compared to patients clinically diagnosed with MPA or who are MPO-positive. Persistent ANCA positivity despite clinical remission is also associated with relapse.<xref ref-type="bibr" rid="article-76416.r31">[31]</xref>&#x000a0;Although immunosuppression therapy longer than 24 months is associated with a decreased relapse risk, the increased infectious risk may not warrant this longer treatment course.</p>
        <p>The following are key points from the 2022 EULAR recommendations for managing ANCA-associated vasculitis.<xref ref-type="bibr" rid="article-76416.r31">[31]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>For new-onset organ/life-threatening GPA (and MPA), induce remission with glucocorticoids and rituximab or cyclophosphamide. Rituximab is preferred for relapsing disease. No significant differences have been found between 2- and 4-dose rituximab infusions.<xref ref-type="bibr" rid="article-76416.r34">[34]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For new-onset non-organ/life-threatening GPA, induce remission with glucocorticoids and rituximab. In some cases, methotrexate and mycophenolate mofetil can be substituted for rituximab. Cyclophosphamide is not preferred due to increased adverse effects, although it is equally effective. A lower dose of prednisolone (0.5 mg/kg/d) can also be considered.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The induction regimen should use oral glucocorticoids at a dose of 50 to 75 mg of prednisolone daily (weight-dependent). Prednisolone should be tapered to 5 mg daily for 4&#x000a0;to 5 months.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Avacopan is an oral C5a receptor antagonist that helps block neutrophil attraction and activation. The ADVOCATE trial demonstrated that avacopan&#x000a0;can be used to induce remission along with rituximab or cyclophosphamide,&#x000a0;effectively reducing glucocorticoid exposure. Avacopan was Food and Drug Administration-approved in 2021 for the treatment of severe ANCA-associated vasculitis.<xref ref-type="bibr" rid="article-76416.r35">[35]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Plasma exchange can be used to induce remission in&#x000a0;patients with glomerulonephritis and a creatinine&#x000a0;level of more than 3.39 mg/dL (300&#x000a0;&#x003bc;mol/L). Routine use of plasma exchange for alveolar hemorrhage in GPA (and MPA) is not recommended. However, plasma exchange is often used as salvage therapy, particularly in patients with a creatinine of more than 5.7 mg/dL.<xref ref-type="bibr" rid="article-76416.r36">[36]</xref> A meta-analysis suggests that&#x000a0;although plasma exchange may reduce the risk of end-stage renal disease, it also increases the risk of infections within the first year.<xref ref-type="bibr" rid="article-76416.r37">[37]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For maintenance of remission, rituximab is recommended. Azathioprine or methotrexate can also be considered, but&#x000a0;their use should be reserved for patients with eGFR more than 60 mL/min/1.73m<sup>2</sup>.<xref ref-type="bibr" rid="article-76416.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For new-onset disease, maintenance should be continued for 24 to 48 months after the onset of remission. A longer treatment duration should be considered for patients with relapsing disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clinical assessment rather than ANCA or CD+19 B-cell levels should guide treatment decisions.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If rituximab is used, serum immunoglobulin levels should be measured before each dose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients on rituximab, cyclophosphamide, or high-dose glucocorticoids, prophylaxis with trimethoprim-sulfamethoxazole should be administered.</p>
          </list-item>
        </list>
        <p>
<bold>Rituximab Versus Cyclophosphamide&#x000a0;</bold>
</p>
        <p>According to the RAVE and RITUXIVAS trials, rituximab was found to be non-inferior to daily cyclophosphamide for the induction of remission in ANCA-associated vasculitis, with a potential advantage in relapsing disease. Notably, cyclophosphamide is considered to have a faster onset of action compared to rituximab,&#x000a0;which should be considered when rapid symptom control is necessary.<xref ref-type="bibr" rid="article-76416.r30">[30]</xref><xref ref-type="bibr" rid="article-76416.r38">[38]</xref><xref ref-type="bibr" rid="article-76416.r39">[39]</xref> In the RITUXIVAS trial, intravenous cyclophosphamide was administered during the first six weeks due to the high prevalence of rapidly progressive glomerulonephritis. The study evaluated&#x000a0;rituximab's effectiveness in maintaining immunosuppression and its impact on long-term prognosis.</p>
        <p>Another consideration is that although the combination of cyclophosphamide and high-dose glucocorticoids is effective in 90% of ANCA-associated vasculitis cases, the 1-year mortality is about 15%, primarily related to active vasculitis and infections. Rituximab has not been associated with significantly increased infectious risks or profound leukopenia when used for rheumatoid arthritis and non-Hodgkin lymphoma; however, studies have not shown it to have lower rates of early severe adverse events compared to cyclophosphamide.<xref ref-type="bibr" rid="article-76416.r39">[39]</xref></p>
        <p>The KDIGO 2021 guidelines suggest considering rituximab and cyclophosphamide if serum creatinine exceeds&#x000a0;4.0; however, the ACR and EULAR guidelines do not endorse this approach.<xref ref-type="bibr" rid="article-76416.r36">[36]</xref></p>
        <p>
<bold>Additional Therapeutics</bold>
</p>
        <p><bold>Plasmapheresis: </bold>Plasmapheresis is considered in cases of rapidly declining kidney function, presence of positive anti-glomerular basement membrane antibodies, or pulmonary hemorrhage complicated by respiratory compromise that does not respond to intravenous glucocorticoids.</p>
        <p><bold>Pulse steroids: </bold>Pulse steroids have not been shown more effective compared to oral steroids, and observational data suggest an increased risk of infection without added benefit.<xref ref-type="bibr" rid="article-76416.r31">[31]</xref></p>
        <p><bold>Methotrexate: </bold>The use of methotrexate for the induction of disease remission rather than cyclophosphamide has also been studied, and 2015 EULAR recommendations suggest methotrexate only for mild and non-organ-threatening diseases. In addition, a low threshold to switch from methotrexate to stronger immunosuppressive may be warranted.<xref ref-type="bibr" rid="article-76416.r30">[30]</xref></p>
        <p><bold>Mycophenolate mofetil: </bold>Mycophenolate mofetil is recommended primarily for anti-MPO-positive disease and is less preferred in cases with anti-PR3 positivity.<xref ref-type="bibr" rid="article-76416.r36">[36]</xref></p>
        <p>
<bold>Key Trials Informing Treatment for ANCA-Associated Vasculitis</bold>
</p>
        <p>The ADVOCATE trial compared the use of avacopan to glucocorticoids (along with rituximab or cyclophosphamide) and found greater renal recovery and increased remission at 1 year in the avacopan group. Although glucocorticoids were still used in the avacopan group, the dose was reduced by about two-thirds, resulting in fewer infections and serious adverse events in this group.<xref ref-type="bibr" rid="article-76416.r31">[31]</xref><xref ref-type="bibr" rid="article-76416.r35">[35]</xref></p>
        <p>The RITUXVAS trial assessed the efficacy of combining rituximab with cyclophosphamide for induction compared to cyclophosphamide with azathioprine for maintenance and found higher adverse events/infections in the combination group after 2 years. Another randomized controlled trial investigating combination therapy is ongoing (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03942887">NCT03942887</ext-link>).<xref ref-type="bibr" rid="article-76416.r34">[21]</xref><xref ref-type="bibr" rid="article-76416.r36">[36]</xref>&#x000a0;</p>
        <p>The MYCYC trial comparing mycophenolate mofetil to cyclophosphamide showed higher relapse rates with mycophenolate mofetil. As a result, mycophenolate mofetil is recommended only if rituximab or cyclophosphamide is not tolerated.<xref ref-type="bibr" rid="article-76416.r30">[30]</xref>&#x000a0;</p>
        <p>The MAINRITSAN and RITAZAREM trials demonstrated the superiority of rituximab to azathioprine for maintenance therapy. Rituximab biosimilars have shown similar performance to rituximab in clinical trials.<xref ref-type="bibr" rid="article-76416.r31">[31]</xref></p>
        <p>The REMAIN, AZA-ANCA, and MAINRITSAN-3 trials all showed reduced relapse and end-stage renal disease with maintenance immunosuppression (both azathioprine and rituximab were studied) lasting 36&#x000a0;to 48 months compared to 18&#x000a0;to 36 months.<xref ref-type="bibr" rid="article-76416.r31">[31]</xref><xref ref-type="bibr" rid="article-76416.r34">[34]</xref></p>
        <p>Maintenance therapy is initiated once remission is achieved, typically within 3 months. Patients are transitioned to maintenance therapy to avoid relapses. The preference for agent selection depends on whether the patient has been newly diagnosed or has more than&#x000a0;1 relapse. Other factors that influence the choice of the maintenance agent used include a prior history of toxicity or comorbidity that increases the risk of toxicity to a particular agent. Maintenance therapy typically lasts 12 to 36 months after remission,&#x000a0;but in high-risk patients, it may be continued indefinitely.</p>
        <p>Patients with drug-induced ANCA vasculitis typically&#x000a0;do not require maintenance therapy.<xref ref-type="bibr" rid="article-76416.r31">[31]</xref></p>
        <p>Refractory disease lacks standardized treatment recommendations. As noted above, plasmapheresis and IVIG have been used as salvage therapy. The use of alemtuzumab in refractory ANCA-associated vasculitis was appraised in the open-label ALLEVIATE trial and found complete or partial remission in 5 of 12 patients (42%) at 1 year.<xref ref-type="bibr" rid="article-76416.r34">[34]</xref></p>
        <p>Double antibody-positive disease occurs in about 10% of patients with rapidly progressive glomerulonephritis, where they test positive for both ANCA and anti-GBM antibodies. The clinical significance is that these patients may significantly benefit from plasmapheresis, as recommended for anti-GBM disease.<xref ref-type="bibr" rid="article-76416.r31">[31]</xref></p>
      </sec>
      <sec id="article-76416.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Due to the multisystemic nature of GPA, the differential diagnosis is broad.&#x000a0;Several conditions that can mimic GPA must be ruled out before a definitive diagnosis can be made.</p>
        <list list-type="bullet">
          <list-item>
            <p>Other forms of ANCA-associated vasculitis:
<list list-type="bullet"><list-item><p>MPA</p></list-item><list-item><p>Churg-Strauss syndrome</p></list-item><list-item><p>Drug-induced ANCA-associated vasculitis</p></list-item><list-item><p>Renal-limited vasculitis</p></list-item><list-item><p>Mixed cryoglobulinemia</p></list-item><list-item><p>Polyarteritis nodosa</p></list-item><list-item><p>Immunoglobulin&#x000a0;A&#x000a0; vasculitis (Henoch-Sch&#x000f6;nlein purpura)</p></list-item><list-item><p>Goodpasture syndrome</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Other autoimmune disorders:&#x000a0;
<list list-type="bullet"><list-item><p>Systemic lupus erythematosus</p></list-item><list-item><p>Sarcoidosis</p></list-item><list-item><p>Rheumatoid arthritis</p></list-item><list-item><p>Amyloidosis</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Infections:&#x000a0;
<list list-type="bullet"><list-item><p>Infective endocarditis</p></list-item><list-item><p>Sepsis</p></list-item><list-item><p>Mycobacterial infections</p></list-item><list-item><p>Disseminated fungal infections</p></list-item><list-item><p>Disseminated gonococcal infection</p></list-item><list-item><p>Streptococcal pneumonia with glomerulonephritis</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Malignancies:
<list list-type="bullet"><list-item><p>Lymphomatoid granulomatosis</p></list-item><list-item><p>Lymphomas</p></list-item><list-item><p>Castleman's disease</p></list-item><list-item><p>Carcinomatosis</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Miscellaneous:
<list list-type="bullet"><list-item><p>Idiopathic pulmonary alveolar hemorrhage</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-76416.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Neutrophil surface SEMA4D is a potential therapeutic target for ANCA-associated vasculitis, as it is a negative regulator of neutrophil activation.<xref ref-type="bibr" rid="article-76416.r40">[40]</xref></p>
        <p>Cathepsin C is another potential therapeutic target, as it plays a role in the maturation of PR3. Inhibiting cathepsin C could potentially reduce autoantigen PR3 and anti-PR3 ANCA levels.<xref ref-type="bibr" rid="article-76416.r5">[5]</xref></p>
      </sec>
      <sec id="article-76416.s12" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>The immunosuppressive agents used in the treatment of GPA have significant adverse effects and can cause complications potentially worse than the disease itself. The most common adverse&#x000a0;effects are&#x000a0;as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Glucocorticoids
<list list-type="bullet"><list-item><p>Hypertension&#x000a0;</p></list-item><list-item><p>Diabetes mellitus</p></list-item><list-item><p>Arrhythmias&#x000a0;</p></list-item><list-item><p>Gastrointestinal bleeding&#x000a0;</p></list-item><list-item><p>Cataract</p></list-item><list-item><p>Glaucoma&#x000a0;</p></list-item><list-item><p>Avascular necrosis of bone</p></list-item><list-item><p>Osteoporosis</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Methotrexate
<list list-type="bullet"><list-item><p>Hepatotoxicity</p></list-item><list-item><p>Stomatitis&#x000a0;</p></list-item><list-item><p>Pneumonitis</p></list-item><list-item><p>Bone marrow suppression</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Cyclophosphamide
<list list-type="bullet"><list-item><p>Bone marrow suppression</p></list-item><list-item><p>Infections&#x000a0;</p></list-item><list-item><p>Gonadal toxicity&#x000a0;</p></list-item><list-item><p>Hemorrhagic cystitis</p></list-item><list-item><p>Bladder carcinoma</p></list-item><list-item><p>Hyponatremia due to SIADH (syndrome of inappropriate antidiuretic hormone secretion)</p></list-item><list-item><p>Myelodysplasia</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Rituximab
<list list-type="bullet"><list-item><p>Progressive multifocal leukoencephalopathy</p></list-item><list-item><p>Infusion reactions&#x000a0;</p></list-item><list-item><p>Opportunistic infections</p></list-item><list-item><p>Late-onset neutropenia</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-76416.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>A study found that after a median follow-up of 28 months, patients with a urine protein-to-creatine ratio of more than 0.05 g/mmol were significantly associated with a risk of kidney failure and death. Persistent hematuria was also associated with worse outcomes,&#x000a0;although to a lesser extent.<xref ref-type="bibr" rid="article-76416.r41">[41]</xref></p>
        <p>GPA is associated with significant morbidity and mortality either due to irreversible organ dysfunction or due to the consequences of intensive/prolonged use of glucocorticoids and immunosuppressive agents. The average life expectancy for a patient with GPA without any treatment is 5 months, with a 1-year survival rate of less than 20%.<xref ref-type="bibr" rid="article-76416.r22">[22]</xref>&#x000a0;More than 80% of treated patients have recently survived at least 8 to 9 years.&#x000a0;This improvement in survival rates is particularly notable as the disease primarily affects individuals older than 65. With advances in treatment, patients also have a higher long-term survival rate and have been able to lead a relatively normal life.<xref ref-type="bibr" rid="article-76416.r27">[27]</xref></p>
      </sec>
      <sec id="article-76416.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Common complications due to the disease itself include the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Hearing loss&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Permanent vision loss</p>
          </list-item>
          <list-item>
            <p>Saddle nose deformity or septal perforation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acute hypoxic respiratory failure due to diffuse pulmonary hemorrhage</p>
          </list-item>
          <list-item>
            <p>Chronic kidney disease and end-stage renal disease&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Mononeuritis multiplex&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Increased risk of heart disease, diabetes, and hypertension due to the vasculitis process and its treatment</p>
          </list-item>
        </list>
        <p>Complications due to immunosuppressive treatment include the following: (please refer to the <bold>T</bold><bold>oxicity and Adverse Effect Management&#x000a0;</bold>for more information)</p>
        <list list-type="bullet">
          <list-item>
            <p>Infections</p>
          </list-item>
          <list-item>
            <p>Cancers, including lymphomas and myelodysplastic syndromes</p>
          </list-item>
          <list-item>
            <p>Infusion reactions and death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-76416.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Living with GPA can be extremely challenging. Patients often face fatigue, pain, disease-related complications, medication side effects, and emotional stress, all of which can significantly impact their well-being, work, and personal relationships. Sharing experiences and difficulties with clinicians, family, and friends and connecting with them through a support group can help immensely. Due to the multisystemic nature of GPA, patients typically require care from multiple healthcare providers, making it crucial to adhere to follow-up appointments and treatment plans. Keeping a journal to track medications and appointments can be a helpful tool in managing the complexities of the condition.</p>
      </sec>
      <sec id="article-76416.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Providing patient-centered care for individuals with GPA requires a collaborative effort among healthcare professionals, including clinicians, advanced practice practitioners, pharmacists, and other healthcare providers. Healthcare providers must possess the necessary clinical skills and expertise&#x000a0;when diagnosing, evaluating, and treating this complex multisystemic condition, including proficiency in interpreting laboratory and radiological findings and recognizing potential complications.</p>
        <p>GPA is a multisystemic disease that requires&#x000a0;an interprofessional team&#x000a0;to cover the broad spectrum of organ involvement. Rheumatologists, pulmonologists, otolaryngologists, pathologists, radiologists, pharmacists, cardiologists, and nephrologists play crucial roles in managing GPA. Effective communication among these team members is key to successful patient care. Nurses are critical in monitoring vital checks and measuring urine output. They also provide immediate care to the patient and monitor them closely during infusions for adverse effects. Many patients with GPA often see multiple specialists, underscoring the importance of a coordinated, collaborative effort.&#x000a0;Effective interprofessional communication fosters a collaborative environment where information is shared, questions are encouraged, and concerns are addressed promptly.</p>
        <p>Lastly, care coordination is crucial in ensuring seamless and efficient patient care. Clinicians, advanced practitioners, pharmacists, and other healthcare providers must collaborate to streamline the patient's journey, from diagnosis through treatment and follow-up. This coordination minimizes errors, reduces delays, and enhances patient safety, ultimately leading to improved outcomes.&#x000a0;By prioritizing the well-being and satisfaction of those affected by GPA, care coordination plays a vital role in delivering patient-centered care.</p>
      </sec>
      <sec id="article-76416.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=76416&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=76416">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/granulomatosis-with-polyangiitis-wegener-granulomatosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=76416">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/76416/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=76416">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-76416.s18">
        <title>References</title>
        <ref id="article-76416.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bacon</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ferrario</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Flores-Suarez</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kallenberg</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Lamprecht</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Langford</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ozen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</article-title>
            <source>Arthritis Rheum</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">23045170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>GODMAN</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>CHURG</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Wegener's granulomatosis: pathology and review of the literature.</article-title>
            <source>AMA Arch Pathol</source>
            <year>1954</year>
            <month>Dec</month>
            <volume>58</volume>
            <issue>6</issue>
            <fpage>533</fpage>
            <page-range>533-53</page-range>
            <pub-id pub-id-type="pmid">13217569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walulik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x00141;ysak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>B&#x00142;aszkiewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000f3;recki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gomu&#x00142;ka</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Role of Neutrophils in ANCA-Associated Vasculitis: The Pathogenic Role and Diagnostic Utility of Autoantibodies.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Dec</month>
            <day>07</day>
            <volume>24</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">38139045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cartin-Ceba</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peikert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of ANCA-associated vasculitis.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>481</fpage>
            <page-range>481-93</page-range>
            <pub-id pub-id-type="pmid">22927039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Korkmaz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nouar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>SAI</given-names>
              </name>
              <name>
                <surname>Jenne</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Lemoine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hoarau</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.</article-title>
            <source>Front Immunol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>571933</fpage>
            <pub-id pub-id-type="pmid">33679731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kessenbrock</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Krumbholz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;nermarck</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Back</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Werb</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gr&#x000f6;ne</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Brinkmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jenne</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Netting neutrophils in autoimmune small-vessel vasculitis.</article-title>
            <source>Nat Med</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>623</fpage>
            <page-range>623-5</page-range>
            <pub-id pub-id-type="pmid">19448636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Clinical features and outcomes of patients with antineutrophil cytoplasmic antibody-positive systemic lupus erythematosus.</article-title>
            <source>Ren Fail</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>2235431</fpage>
            <pub-id pub-id-type="pmid">37470370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Peh</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Szpirt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>De Zoysa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ives</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Quillen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Winters</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <collab>PEXIVAS Investigators</collab>
            </person-group>
            <article-title>Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial.</article-title>
            <source>Trials</source>
            <year>2013</year>
            <month>Mar</month>
            <day>14</day>
            <volume>14</volume>
            <fpage>73</fpage>
            <pub-id pub-id-type="pmid">23497590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papiha</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Murty</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Ad'Hia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mains</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Venning</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Association of Wegener's granulomatosis with HLA antigens and other genetic markers.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1992</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>246</fpage>
            <page-range>246-8</page-range>
            <pub-id pub-id-type="pmid">1550412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nikkari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mertsola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Korvenranta</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vainionp&#x000e4;&#x000e4;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Toivanen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Wegener's granulomatosis and parvovirus B19 infection.</article-title>
            <source>Arthritis Rheum</source>
            <year>1994</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>11</issue>
            <fpage>1707</fpage>
            <page-range>1707-8</page-range>
            <pub-id pub-id-type="pmid">7980681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hogan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced glomerular disease: immune-mediated injury.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2015</year>
            <month>Jul</month>
            <day>07</day>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>1300</fpage>
            <page-range>1300-10</page-range>
            <pub-id pub-id-type="pmid">26092827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anguiano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>The glomerular crescent: triggers, evolution, resolution, and implications for therapy.</article-title>
            <source>Curr Opin Nephrol Hypertens</source>
            <year>2020</year>
            <month>May</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>302</fpage>
            <page-range>302-309</page-range>
            <pub-id pub-id-type="pmid">32132388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arimura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Muso</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaname</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Usui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ihara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Itabashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kitagawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hirahashi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>322</fpage>
            <page-range>322-41</page-range>
            <pub-id pub-id-type="pmid">27099135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacheco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Double-Positive Anti-GBM and ANCA-MPO Vasculitis Presenting With Crescentic Glomerulonephritis.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>May</month>
            <day>02</day>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>e14806</fpage>
            <pub-id pub-id-type="pmid">34094762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clerte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cornec-Le Gall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Audard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Huart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pu&#x000e9;chal</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Touzot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rabot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thervet</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Aouba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karras</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Renal and overall outcomes of double-positive (ANCA and anti-GBM antibodies) patients compared to ANCA-associated vasculitis patients with severe renal involvement: A multicenter retrospective study with systematic renal pathology analysis.</article-title>
            <source>Scand J Rheumatol</source>
            <year>2022</year>
            <month>May</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>205</fpage>
            <page-range>205-213</page-range>
            <pub-id pub-id-type="pmid">34169779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ntatsaki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of ANCA-associated vasculitis.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>447</fpage>
            <page-range>447-61</page-range>
            <pub-id pub-id-type="pmid">20688243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dirikgil</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jonker</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Tas</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Verburgh</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Soonawala</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hak</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Remmelts</surname>
                <given-names>HHF</given-names>
              </name>
              <name>
                <surname>IJpelaar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Laverman</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Rutgers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Laar</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Moen</surname>
                <given-names>HJB</given-names>
              </name>
              <name>
                <surname>Verhoeven</surname>
                <given-names>PMJ</given-names>
              </name>
              <name>
                <surname>Rabelink</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bos</surname>
                <given-names>WJW</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>YKO</given-names>
              </name>
              <collab>Arthritis Research &#x00026; Collaboration Hub (ARCH) study group</collab>
            </person-group>
            <article-title>Clinical Practice Audit on the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Netherlands.</article-title>
            <source>Kidney Int Rep</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>10</issue>
            <fpage>2671</fpage>
            <page-range>2671-2678</page-range>
            <pub-id pub-id-type="pmid">34622106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iudici</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quartier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pu&#x000e9;chal</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2016</year>
            <month>Oct</month>
            <day>22</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <pub-id pub-id-type="pmid">27770813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Csernok</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Current understanding of the pathogenesis of granulomatosis with polyangiitis (Wegener's).</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>641</fpage>
            <page-range>641-8</page-range>
            <pub-id pub-id-type="pmid">23899234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filocamo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Torreggiani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agostoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Lung involvement in childhood onset granulomatosis with polyangiitis.</article-title>
            <source>Pediatr Rheumatol Online J</source>
            <year>2017</year>
            <month>Apr</month>
            <day>14</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <pub-id pub-id-type="pmid">28410589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Standardized classification and reporting of glomerulonephritis.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-199</page-range>
            <pub-id pub-id-type="pmid">30124958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dharamdasani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhalla</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bhargava</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rana</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Sapra</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Factors Influencing Outcomes in Pauci-Immune Crescentic Glomerulonephritis: Single Centre Experience of 51 Cases.</article-title>
            <source>Indian J Nephrol</source>
            <year>2021</year>
            <season>Nov-Dec</season>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>503</fpage>
            <page-range>503-506</page-range>
            <pub-id pub-id-type="pmid">35068754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>DeRemee</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Granulomatous vasculitis. Wegener's granulomatosis and Churg-Strauss syndrome.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>1990</year>
            <month>May</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>377</fpage>
            <page-range>377-97</page-range>
            <pub-id pub-id-type="pmid">2189156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Comarmond</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cacoub</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment.</article-title>
            <source>Autoimmun Rev</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>1121</fpage>
            <page-range>1121-5</page-range>
            <pub-id pub-id-type="pmid">25149391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leavitt</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Fauci</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Arend</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Calabrese</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Fries</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lie</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Lightfoot</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.</article-title>
            <source>Arthritis Rheum</source>
            <year>1990</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>1101</fpage>
            <page-range>1101-7</page-range>
            <pub-id pub-id-type="pmid">2202308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeREMEE</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Coles</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Wegener's granulomatosis. Anatomic correlates, a proposed classification.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1976</year>
            <month>Dec</month>
            <volume>51</volume>
            <issue>12</issue>
            <fpage>777</fpage>
            <page-range>777-81</page-range>
            <pub-id pub-id-type="pmid">994555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinching</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lockwood</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Pussell</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sweny</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bowley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Wegener's granulomatosis: observations on 18 patients with severe renal disease.</article-title>
            <source>Q J Med</source>
            <year>1983</year>
            <season>Autumn</season>
            <volume>52</volume>
            <issue>208</issue>
            <fpage>435</fpage>
            <page-range>435-60</page-range>
            <pub-id pub-id-type="pmid">6657912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Grayson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Ponte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Suppiah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Craven</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khalid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hutchings</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <collab>DCVAS Investigators</collab>
            </person-group>
            <article-title>2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-320</page-range>
            <pub-id pub-id-type="pmid">35110333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moiseev</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cohen Tervaert</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Arimura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bogdanos</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Csernok</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Damoiseaux</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferrante</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flores-Su&#x000e1;rez</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Fritzler</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>McAdoo</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Novikov</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Radice</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Savige</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shoenfeld</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sinico</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tzioufas</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Vermeire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Bossuyt</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>2020 international consensus on ANCA testing beyond systemic vasculitis.</article-title>
            <source>Autoimmun Rev</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>102618</fpage>
            <pub-id pub-id-type="pmid">32663621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Offiah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jawad</surname>
                <given-names>ASM</given-names>
              </name>
            </person-group>
            <article-title>Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review.</article-title>
            <source>BMC Neurol</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <pub-id pub-id-type="pmid">29716529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hellmich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sanchez-Alamo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schirmer</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blockmans</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Holle</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Hollinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Karadag</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kronbichler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mohammad</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mukhtyar</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Musial</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Price-Kuehne</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>YKO</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tomasson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vaglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vassilopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verhoeven</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2024</year>
            <month>Jan</month>
            <day>02</day>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-47</page-range>
            <pub-id pub-id-type="pmid">36927642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tadema</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McKinney</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Benharkou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brandes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peschel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hubert</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Feenstra</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seng&#x000f6;lge</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stegeman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heeringa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Kallenberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>556</fpage>
            <page-range>556-66</page-range>
            <pub-id pub-id-type="pmid">22323643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holle</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Holl-Ulrich</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ambrosch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Noelle</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Both</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Csernok</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moosig</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schinke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reinhold-Keller</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?</article-title>
            <source>Ann Rheum Dis</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>69</volume>
            <issue>11</issue>
            <fpage>1934</fpage>
            <page-range>1934-9</page-range>
            <pub-id pub-id-type="pmid">20511614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schirmer</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sanchez-Alamo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hellmich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Tomasson</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1-treatment of granulomatosis with polyangiitis and microscopic polyangiitis.</article-title>
            <source>RMD Open</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">37479496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jayne</surname>
                <given-names>DRW</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Schall</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bekker</surname>
                <given-names>P</given-names>
              </name>
              <collab>ADVOCATE Study Group</collab>
            </person-group>
            <article-title>Avacopan for the Treatment of ANCA-Associated Vasculitis.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Feb</month>
            <day>18</day>
            <volume>384</volume>
            <issue>7</issue>
            <fpage>599</fpage>
            <page-range>599-609</page-range>
            <pub-id pub-id-type="pmid">33596356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casal Moura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gauckler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Bruchfeld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fernandez-Juarez</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frangou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goumenos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turkmen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Kooten</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Geetha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DRW</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Kronbichler</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2023</year>
            <month>Oct</month>
            <day>31</day>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>2637</fpage>
            <page-range>2637-2651</page-range>
            <pub-id pub-id-type="pmid">37164940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collister</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Au Peh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Szpirt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ito-Hara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DRW</given-names>
              </name>
              <collab>Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis BMJ Rapid Recommendations Group</collab>
            </person-group>
            <article-title>The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis.</article-title>
            <source>BMJ</source>
            <year>2022</year>
            <month>Feb</month>
            <day>25</day>
            <volume>376</volume>
            <fpage>e064604</fpage>
            <pub-id pub-id-type="pmid">35217545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Spiera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Langford</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Kallenberg</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>St Clair</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Turkiewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tchao</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Webber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sejismundo</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Mieras</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weitzenkamp</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ikle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seyfert-Margolis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brunetta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Geetha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Kissin</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Monach</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Peikert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stegeman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ytterberg</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <collab>RAVE-ITN Research Group</collab>
            </person-group>
            <article-title>Rituximab versus cyclophosphamide for ANCA-associated vasculitis.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Jul</month>
            <day>15</day>
            <volume>363</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-32</page-range>
            <pub-id pub-id-type="pmid">20647199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Tervaert</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Peh</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>van Paassen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Westman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DR</given-names>
              </name>
              <collab>European Vasculitis Study Group</collab>
            </person-group>
            <article-title>Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Jul</month>
            <day>15</day>
            <volume>363</volume>
            <issue>3</issue>
            <fpage>211</fpage>
            <page-range>211-20</page-range>
            <pub-id pub-id-type="pmid">20647198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishide</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nojima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Takamatsu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Koyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morimoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hosokawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hayama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kinehara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakatani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Narazaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morii</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kumanogoh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>76</volume>
            <issue>8</issue>
            <fpage>1440</fpage>
            <page-range>1440-1448</page-range>
            <pub-id pub-id-type="pmid">28416516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-76416.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benichou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Hiemstra</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bajema</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Berden</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thervet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karras</surname>
                <given-names>A</given-names>
              </name>
              <collab>French Vasculitis Study Group (FVSG) and European Vasculitis Society (EUVAS) investigators</collab>
            </person-group>
            <article-title>Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis.</article-title>
            <source>Kidney Int</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>103</volume>
            <issue>6</issue>
            <fpage>1144</fpage>
            <page-range>1144-1155</page-range>
            <pub-id pub-id-type="pmid">36940799</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
